Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 20,000 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CAO Edward Carr sold 20,000 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the transaction, the chief accounting officer directly owned 20,000 shares in the company, valued at $2,027,600. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Dianthus Therapeutics Price Performance

Shares of DNTH traded down $4.31 during trading hours on Friday, hitting $96.81. 2,829,340 shares of the company were exchanged, compared to its average volume of 933,748. The company has a market capitalization of $5.29 billion, a PE ratio of -23.33 and a beta of 1.24. The firm has a fifty day simple moving average of $107.04 and a 200-day simple moving average of $92.81. Dianthus Therapeutics, Inc. has a one year low of $32.22 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Sell-side analysts expect that Dianthus Therapeutics, Inc. will post -3.81 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Horizon Corp acquired a new position in Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics during the fourth quarter valued at approximately $43,000. EFG International AG acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $49,000. Global Retirement Partners LLC acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $93,000. Finally, Nykredit A S bought a new stake in Dianthus Therapeutics in the second quarter worth approximately $147,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on DNTH. Citigroup started coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 target price on the stock. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. JPMorgan Chase & Co. began coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.83.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.